首页> 美国卫生研究院文献>Oncoimmunology >Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
【2h】

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

机译:低CD4⁺/CD25⁺/CD127⁻调节性T细胞水平和高INF-γ水平与长期输注ch14.18 / CHO联合白介素2治疗的神经母细胞瘤患者的存活率提高相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immunotherapy with the anti-GD antibody (Ab) ch14.18/CHO in combination with interleukin 2 (IL-2) has improved survival of high-risk neuroblastoma (NB) patients. Here, we report immunotherapy-related effects on circulating NK cells, regulatory T cells (T ), granulocytes as well as on Ab-dependent cell-mediated cytotoxicity (ADCC) and cytokines IFN-γ, IL-6, IL-10, IL-18 and CCL2 and their association with progression-free survival (PFS).
机译:抗GD抗体(Ab)ch14.18 / CHO与白介素2(IL-2)联合进行的免疫治疗可提高高危神经母细胞瘤(NB)患者的生存率。在这里,我们报告免疫疗法对循环NK细胞,调节性T细胞(T),粒细胞以及对Ab依赖性细胞介导的细胞毒性(ADCC)和细胞因子IFN-γ,IL-6,IL-10,IL的免疫治疗相关作用-18和CCL2及其与无进展生存期(PFS)的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号